THE RATIO OF TrkA AND p75 RECEPTORS ON THE CELL NEUROEPITHELIAL TUMORS – A NEW TARGET EFFECT OF NERVE GROWTH FACTOR WITH CISPLATIN AND TEMOZOLOMIDE AND THE COMBINATIONS
https://doi.org/10.17650/2222-1468-2016-6-4-53-61
Abstract
Objective. To study the change of expression of TrkA, p75 receptors and their ratio on the human anaplastic astrocytoma, glioblastoma and medulloblastoma cells cultures exposed to nerve growth factor (NGF) and its combination with cisplatin or temozolomide, to establish participation of expression of the receptors in sensitivity tumor cells to NGF and its combinations with chemotherapeutical drugs.
Materials and methods. In primary cell cultures of anaplastic astrocytoma, glioblastoma and medulloblastoma were studied: 1) cytotoxicity effects of nerve growth factor and its combination with cisplatin or temozolomide; 2) the expression of TrkA, p75 receptors and the its ratio by immunofluorescence; 3) correlation between expression of TrkA, p75 receptors, the its ratio and index of cytotoxicity of reagents.
Results. It is found that the expression of the receptors and the relationship depends on the tumor type and reagents’ mechanism of action. Expression of TrkA and p75 receptors and their ratio correlated with sensitivity of anaplastic astrocytoma and glioblastoma cells to NGF and its combination with cisplatin or temozolomide.
Conclusion. Relative expression of TrkA/p75 receptor, and its coefficient of correlation with index of cytotoxicity point to a mechanism (signaling pathway), on which there is cell death.
About the Author
A. N. Chernov
Institute of Physiology, National Academy of Sciences of Belarus
Belarus
Belarus
28 Akademicheskaya St., Minsk 220072
References
1. Grauer O., Pascher Ch., Hartmann Ch. et al. Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). J Neurooncol 2011;104(3):801–9.
2. Савва Н.Н., Зборовская А.А., Алейникова О.В. Злокачественные новообразования у детей Беларуси: заболеваемость, выживаемость, смертность, подходы к паллиативной помощи. Минск, 2008. 180 с. [Savva N.N., Zborovskaya A.A., Aleynikova O.V. Malignant tumors in children of Belarus: incidence, survival, mortality approaches to palliative care. Minsk, 2008. 180 p. (In Russ.)].
3. Lafai-Cousin L., Strother D. Current treatment approaches for infants with malignant central nervous system tumors. Oncologist 2009;14:433–44.
4. Конопля Н.Е. Лечение медуллобластомы у детей младше 4 лет. Meдицинский журнал 2009;(1):112–4. [Коnоplya N.Е. Treatment of medulloblastoma in children younger than 4 years. Meditsinskiy zhurnal = Medical Journal 2009;(1):112–4. (In Russ.)].
5. Bobustuc G.C., Baker C.H., Limaye A. et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neurooncology 2010; 12(9):917–27.
6. Kokunai T., Iguchi H., Tamaki N. Differentiation and growth inhibition of glioma cells induced by transfer of trk A proto-oncogene. J Neurooncol 1999;42(1): 23–34.
7. Борисов К.Е., Сакаева Д.Д. Таргетная терапия злокачественных глиом: состояние проблемы. Российский онкологический журнал 2011;(3):47–53. [Bоrisоv К.Е., Sаkаеvа D.D. Targeted therapy of malignant gliomas: state of the problem. Rossiyskiy onkologicheskiy zhurnal = Russian Oncological Journal 2011;(3):47–53. (In Russ.)].
8. Церковский Д.А. Соно-фотодинамическая терапия – новый метод лечения злокачественных опухолей мозга. Онкологический журнал 2015;9(1):94–106. [Tserkovskiy D.А. Sono-photodymanic therapy – a new method in the treatment of maligant brain tumors. Onkologicheskiy zhurnal = Oncological Journal 2015;9(1):94–106. (In Russ.)].
9. Pimentel E. Handbook of growth factors. In 3 vol. London, Tokyo: CRC Press Inc, 1994. Vol. 2, Ch. 5: Neurotrophic growth factors. Pр. 217–40.
10. Калюнов В.Н. Биология фактора роста нервной ткани. Минск: Наука и техника, 1986. 206 с. [Каlyunоv V.N. Biоlоgy of the growth factor of nervous tissue. Мinsk: Nauka i tekhnika, 1986. 206 p. (In Russ.)].
11. Tacconelli A., Farina A.R., Cappabianca L. et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004;6(4):347–60.
12. Чернов А.Н., Талабаев М.В., Конопля Н.Е. и др. Влияние химиопрепаратов и фактора роста нервов на выживаемость клеток первичной культуры нейроэпителиальных опухолей. Вестник Национальной академии наук Беларуси. Серия медицинских наук 2013;(1):46–51. [Chernov А.N., Таlаbаеv М.V., Коnоplya N.Е. et al. Action of the nerve growth factor and chemotherapeutical drugs upon the viability of the cells of the neuroepithelial tumor primary culture. Vestnik Natsional’noy akademii nauk Belarusi. Seriya meditsinskikh nauk = Proceedings of the National Academy of Sciences of Bеlarus. Series of Medical Sciences 2013;(1):46–51. (In Russ.)].
13. Чу Э., де Вита В. мл. Химиотерапия злокачественных опухолей. М.: Практика, 2008. 447 с. [Chu E., dе Vitа V. Jr. Chemotherapy of malignant tumors. Мoscow: Praktika, 2008. 447 p. (In Russ.)].
14. Wolff J.E., Kortmann R.-D., Wolff B. et al. High-dose methotrexate for pediatric high grade glioma – results of the HIT-GBM-D pilot study. J Neuroоncol 2011;102(3):433–42.
15. Korade M.Z., Yan C., Portugal C. et al. Expression and p75 neurotrophin receptor dependence of cholesterol synthetic enzymes in adult mouse brain. Neurobiol Aging 2007;28(10):1522–31.
16. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Let 2001;169(2):107–14.
17. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat Rev 2003;3(3):203–15.
18. Brodeur G.M., Nakagawara A., Yamashiro D.J. et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neuroоncol 1997;31(1):249–56.
19. Harel L., Costa B., Fainzilber M. On the death Trk. Dev Neurobiol 2010;70(5):298–303.
20. Божкова В.П., Вепринцев Б.П., Викторов И.В. и др. Руководство по культивированию нервной ткани. Методы. Техника. Проблемы. М.: Наука, 1988. 318 c. [Bоzhkоvа V.P., Vеprintsеv B.P., Viktоrоv I.V. et al. Guidance for cultivation of nervous tissue. Меthоds. Technics. Prоblems. Мoscow: Nauka, 1988. 318 p. (In Russ.)].
21. Freshney R.I. Animal Cell Culture: a Practical Approach. Eds. by: W. Masters 3rd. London: Oxford University Press, 2000. 315 p.
22. Миронов А.Н., Бабаян Н.Д., Васильева A.Н. и др. Руководство по проведению доклинических испытаний лекарственных средств. Ч. 1. М.: Гриф и К, 2012. 944 с. [Мirоnоv А.N., Babayan N.D., Vasil’eva A.N. et al. Guidance for the testing of pre-clinical investigation of medicinal drugs. P. 1. Мoscow: Grif i К, 2012. 944 p. (In Russ.)].
23. Ghinelli E., Johansson J., Rios J.D. et al. Presence and localization of neurotrophins and neurotrophin receptors in rat lacrimal gland. Inv Ophthalmol Visual Sci 2003;44(8):3352–7.
24. van Belle G., Fisher L.D., Heagerty P.J. et al. Biostatistics: a methodology for the health sciences. Canada: Jonh Wiley and Sons Inc, 2004. 889 p.
25. Гланц С. Медицинская и биологическая статистика. М.: Практика, 1999. 356 с. [Glаnts S. Medical and biological statistics. Мoscow: Praktika, 1999. 356 p. (In Russ.)].
26. Krűttgen A., Schneider I., Weis J. The dark side of the NGF family: neurotrophins in neoplasias. Brain Pathol 2006;16(4):304–10.
27. Chen J., Zhe X. Cotransfection of TrkA and p75NTR in neuroblastoma cell line IMR-32 promotes differentiation and apoptosis of tumor cells. Chinease Med J 2003;116(6):906–12.
28. Evangelopoulos M.E., Weis J., Krűttgen A. Neurotrophin effects on neuroblastoma cells: correlation with Trk and p75NTR expression and influence of TrkA receptor bodies. J Neuroоncol 2004;66(1–2):101–10.
29. Heymach J.V., Schooter E.M. The biosyntesis of neurotrophin heterodimeres by transfected mammalian cells. J Biol Chem 1995;270(20):12297–304.
30. Pflug B.R., Colangelo A.M., Tornatore C. et al. TrkA induces differentiation but not apoptosis in C6–2B glioma cells. J Neurosci Res 2001;64(6):636–45.
31. Wadhwa S., Nag T.C., Jindal A. et al. Expression of the neurotrophin receptors TrkA and TrkB in adult human astrocytoma and glioblastoma. J Biosci 2003;28(2): 181–8.
Review
For citations:
Chernov A.N. THE RATIO OF TrkA AND p75 RECEPTORS ON THE CELL NEUROEPITHELIAL TUMORS – A NEW TARGET EFFECT OF NERVE GROWTH FACTOR WITH CISPLATIN AND TEMOZOLOMIDE AND THE COMBINATIONS. Head and Neck Tumors (HNT). 2016;6(4):53-61. (In Russ.) https://doi.org/10.17650/2222-1468-2016-6-4-53-61
Views:
2540
Email this article 